Shaggy Mane (Coprinus comatus)

Shaggy Mane (Coprinus comatus) is a medicinal mushroom containing Y3 protein and bioactive compounds that target androgen receptors and cellular apoptosis pathways. Research shows its ethyl acetate extract can reduce PSA levels by 77% in prostate cancer cells while Y3 protein demonstrates selective anti-cancer activity.

Origin & History

Shaggy Mane (Coprinus comatus) is an edible basidiomycete mushroom from the Agaricomycetidae family, found worldwide on grasslands and organic debris in temperate regions. It is harvested from wild fruiting bodies or cultivated mycelium, with active compounds extracted using solvents like ethyl acetate, hexane, ethanol, or water from fruit bodies, mycelium, or fermentation broth.

Historical & Cultural Context

No documented historical traditional medicine use was found in the research sources. Shaggy Mane has been recognized primarily as an edible mushroom, with medicinal research interest emerging only in the 2010s.

Health Benefits

• Prostate health support: Ethyl acetate extract inhibited androgen receptor activity and PSA levels by 77% in prostate cancer cells (in vitro evidence only)
• Anti-cancer potential: Y3 protein killed 90% of human T-cell leukemia cells through selective apoptosis (laboratory studies only)
• Anti-inflammatory effects: Triglycerides at 30 mg/kg reduced TNF-α by 58% and IL-1β by 27% in mouse models (animal studies only)
• Liver protection: Polysaccharides attenuated inflammatory markers IL-6, iNOS, and COX-2 in alcohol-induced liver inflammation (preclinical evidence)
• Cognitive support: Demonstrated acetylcholinesterase inhibition with IC50 of 0.62 mg/mL, potentially beneficial for Alzheimer's (in vitro data only)

How It Works

Shaggy Mane's ethyl acetate extract inhibits androgen receptor activity, reducing PSA (prostate-specific antigen) expression in prostate cells. The Y3 protein component induces selective apoptosis in cancer cells through mitochondrial pathway activation. Additional compounds may modulate inflammatory cytokines and support immune system regulation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Shaggy Mane mushroom. All available evidence comes from preclinical in vitro studies and animal models, with no PubMed PMIDs provided for human trials in the research sources.

Clinical Summary

Current evidence is limited to in vitro laboratory studies showing 77% reduction in PSA levels and androgen receptor inhibition in prostate cancer cell lines. Separate laboratory research demonstrated Y3 protein killed 90% of human T-cell leukemia cells through targeted apoptosis mechanisms. No human clinical trials have been conducted to validate these preliminary findings. Animal studies and human research are needed to confirm therapeutic potential and establish effective dosing protocols.

Nutritional Profile

Shaggy Mane (Coprinus comatus) provides a low-calorie, high-moisture fruiting body (approximately 90-92% water when fresh). Per 100g dry weight: Protein: 25-30g, comprising all essential amino acids with notable concentrations of glutamic acid, aspartic acid, and lysine (approximately 1.8-2.1g/100g dry weight); Carbohydrates: 50-60g dry weight, predominantly as beta-glucans (estimated 15-20% of dry weight, including (1→3),(1→6)-β-D-glucans with immunomodulatory properties) and chitin (structural component, 5-8% dry weight); Dietary fiber: 15-20g/100g dry weight; Fat: 2-4g/100g dry weight, predominantly unsaturated fatty acids including linoleic acid (C18:2, ~40-50% of total fatty acids) and oleic acid (~20-25% of total fatty acids); the bioactive triglyceride fraction associated with anti-inflammatory effects has been isolated from this lipid fraction. Key micronutrients include potassium (approximately 300-400mg/100g dry weight), phosphorus (200-300mg/100g dry weight), selenium (trace amounts, 0.01-0.05mg/100g dry weight), zinc (3-5mg/100g dry weight), and iron (2-4mg/100g dry weight). Vitamin profile includes niacin (B3, approximately 40-60mg/100g dry weight), riboflavin (B2, 2-4mg/100g dry weight), and ergosterol (provitamin D2 precursor, approximately 50-150mg/100g dry weight, converted to vitamin D2 upon UV exposure). Bioactive compounds include: coprinol (a phenolic compound with antimicrobial properties); the Y3 lectin-like protein associated with selective cytotoxicity; coprinin (an antimicrobial peptide); and ethyl acetate-soluble phenolic fractions with androgen receptor inhibitory activity. Bioavailability note: Chitin cell walls significantly reduce bioavailability of intracellular nutrients; cooking or processing substantially improves protein and mineral bioavailability by disrupting chitin matrix. Beta-glucan bioavailability for immune activity is maintained in both cooked and raw forms. The mushroom autolysates rapidly upon harvesting due to autodigestive enzyme activity (ink cap process), which may alter nutrient composition post-harvest.

Preparation & Dosage

No clinically studied human dosages exist. Preclinical animal studies used triglycerides at 30 mg/kg body weight for anti-inflammatory effects and fermented extracts at 1-5 mg/kg for analgesic activity in mice. In vitro studies used crude solvent extracts without standardization. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Reishi, Turkey Tail, Lion's Mane, Cordyceps, Chaga

Safety & Interactions

Shaggy Mane mushroom is generally considered safe when consumed as food, but supplement safety profiles are not well-established. No documented drug interactions exist, though theoretical concerns include potential effects on hormone-sensitive medications due to androgen receptor activity. Pregnant and breastfeeding women should avoid supplements due to lack of safety data. Individuals with autoimmune conditions should consult healthcare providers before use given potential immune system effects.